Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 7:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 3,676 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diabetes Mellitus, Type II Clear all
Completed Phase 1 Interventional

Exercise Study to Help Patients Who Have Type 2 Diabetes and Depression.

NCT01024790
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Exercise group
Behavioral
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
21 Years to 65 Years · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 9, 2013 · Synced Oct 14, 2026, 7:41 PM EDT
Completed Phase 2 Interventional

A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)

NCT00901979
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
LCQ908A, Placebo, Sitagliptin, metformin
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
693 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
48
States / cities
Mesa, Arizona • Little Rock, Arkansas • Buena Park, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2013 · Synced Oct 14, 2026, 7:41 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Effects of FX006 on Blood Glucose in Patients With OA of the Knee and Type 2 Diabetes

NCT02762370
View directory record Official record
Conditions
Osteoarthritis of the Knee, Type 2 Diabetes Mellitus
Interventions
FX006 32 mg, TCA IR 40 mg
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
40 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
8
States / cities
Anaheim, California • El Cajon, California • North Hollywood, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Oct 14, 2026, 7:41 PM EDT
Completed Phase 1 Interventional

Isoprostane/FMD Study The Effect of Protein Kinase C (PKC) β Specific Inhibitor LY333531 on Oxidant Stress in Patients With Type 2 Diabetes Mellitus

NCT00552227
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
ruboxistaurin, placebo
Drug · Other
Lead sponsor
Chromaderm, Inc.
Industry
Eligibility
35 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 26, 2016 · Synced Oct 14, 2026, 7:41 PM EDT
Completed Not applicable Interventional

An Emotion-Focused Intervention for Glycemic Control in T2D

NCT03553680
View directory record Official record
Conditions
Type2 Diabetes
Interventions
Emotion-Focused CBT
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
21 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 22, 2020 · Synced Oct 14, 2026, 7:41 PM EDT
Completed Not applicable Interventional

Examining The Role of CGM in T2DM

NCT01614262
View directory record Official record
Conditions
DIABETES MELLITUS, NONINSULIN-DEPENDENT, 2 (Disorder)
Interventions
Continuous Glucose Monitoring with treatment algorithm
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Atlanta, Georgia • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Oct 14, 2026, 7:41 PM EDT
Completed Phase 2 Interventional

A Prospective, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedance, in Type 2 Diabetic Subjects With Nephropathy

NCT01399580
View directory record Official record
Conditions
Chronic Kidney Disease, Diabetic Nephropathy
Interventions
Atrasentan, Placebo
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
28
States / cities
Phoenix, Arizona • Tempe, Arizona • Azusa, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2013 · Synced Oct 14, 2026, 7:41 PM EDT
Terminated Phase 4 Interventional Results available

Use of Sitagliptin for Stress Hyperglycemia or Mild Diabetes Following Cardiac Surgery

NCT01970462
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Hyperglycemia
Interventions
Sitagliptin, Placebo
Drug
Lead sponsor
Kathleen Dungan
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Oct 14, 2026, 7:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of 2.5-mg Saxagliptin and 500-mg Glucophage in Tablets and a Fixed-dose Combination Tablet in Healthy Participants

NCT01068717
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Saxagliptin, 2.5 mg + Metformin, 500 mg (fasted state), Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fasted state), Saxagliptin, 2.5 mg + Metformin, 500 mg (fed state), Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fed state)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Oct 14, 2026, 7:41 PM EDT
Terminated Phase 2 Interventional

Efficacy and Safety of TAK-379 in Adult Subjects With Type 2 Diabetes Mellitus

NCT00722917
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
TAK-379, Pioglitazone, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
8
States / cities
Artesia, California • Norwalk, California • Santa Ana, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2016 · Synced Oct 14, 2026, 7:41 PM EDT
Completed No phase listed Observational

Acute Kidney Injury in Patients on Dapagliflozin and Other Antidiabetic Medications

NCT02695082
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Not listed
Lead sponsor
AstraZeneca
Industry
Eligibility
Not listed
Enrollment
539,310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Wilmington, Delaware • Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 7, 2021 · Synced Oct 14, 2026, 7:41 PM EDT
Completed No phase listed Observational

An Observational Study Called FIRST-2.0 to Learn More About the Use of the Study Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions

NCT05703880
View directory record Official record
Conditions
Chronic Kidney Disease, Type 2 Diabetes Mellitus
Interventions
Finerenone (Kerendia, BAY948862)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
15,948 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts • Eden Prairie, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 18, 2024 · Synced Oct 14, 2026, 7:41 PM EDT
Completed No phase listed Observational Results available

Comparison of Type 2 Diabetes Pharmacotherapy Regimens

NCT05073692
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Cardiovascular Diseases
Interventions
SU, DPP4, SGLT2i, GLP-1RA, SGLT2i or GLP-1RA, Linagliptin (DPP4), Exenatide (GLP-1RA), Liraglutide (GLP-1RA), Empagliflozin (SGLT2i), Glimepiride (SU), Glipizide (SU), Glimepiride (SU) or Glipizide (SU), SU or DPP4 (excluding saxagliptin and alogliptin), Exenatide (GLP-1RA) or Liraglutide (GLP-1RA)
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years to 85 Years
Enrollment
241,981 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Pasadena, California • Pleasanton, California • Honolulu, Hawaii + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 14, 2026, 7:41 PM EDT
Terminated No phase listed Observational

GDM Post Partum Screening

NCT03946631
View directory record Official record
Conditions
Diabetes, Gestational Diabetes, Diabetes Mellitus, Type 2
Interventions
2 hour glucose tolerance test using 75g glucose drink
Diagnostic Test
Lead sponsor
Pediatrix
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 14, 2022 · Synced Oct 14, 2026, 7:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Fit 24 Technology Intervention YOUTH

NCT04953442
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Fit 24
Behavioral
Lead sponsor
Baylor College of Medicine
Other
Eligibility
14 Years to 16 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 14, 2026, 7:41 PM EDT
Completed No phase listed Observational

Endotoxin and Intestinal Flora Before and After Gastric Bypass or Banding in Diabetics

NCT00960765
View directory record Official record
Conditions
Obesity, Morbid, Diabetes Mellitus, Type 2, Gastric Bypass
Interventions
Not listed
Lead sponsor
CPL Associates
Other
Eligibility
18 Years to 95 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Buffalo, New York • Williamsville, New York
Source: ClinicalTrials.gov public record
Updated Jan 28, 2016 · Synced Oct 14, 2026, 7:41 PM EDT
Completed Phase 1 Interventional Results available

Study To Compare Single Dose Of Three Modified Release Formulations Of PF-04937319 With Immediate Release Material-Sparing-Tablet (IR MST) Formulation Previously Studied In Adults With Type 2 Diabetes Mellitus.

NCT02206607
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
PF-04937319 IR MST, PF-04937319 MR 1, PF-04937319 MR 2, PF-04937319 MR 3
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
High Point, North Carolina • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2016 · Synced Oct 14, 2026, 7:41 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

The Diabetes Prevention Program Outcomes Study AD/ADRD Project

NCT05704309
View directory record Official record
Conditions
Diabetes, Alzheimer Disease, Dementia, Vascular, Dementia, PreDiabetes
Interventions
Not listed
Lead sponsor
Marinella Temprosa
Other
Eligibility
Not listed
Enrollment
1,976 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
27
States / cities
Phoenix, Arizona • Alhambra, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Oct 14, 2026, 7:41 PM EDT
Completed Phase 2 Interventional

Internet Diabetes Self-Management

NCT00372463
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
6-week Online Diabetes Self-Management Educational Program
Behavioral
Lead sponsor
Robert Wood Johnson Foundation
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 27, 2011 · Synced Oct 14, 2026, 7:41 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes

NCT01652716
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Exenatide once weekly suspension, Exenatide twice daily
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
58
States / cities
Muscle Shoals, Alabama • Mesa, Arizona • Phoenix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2018 · Synced Oct 14, 2026, 7:41 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)

NCT01234649
View directory record Official record
Conditions
Gestational Diabetes Mellitus, Type 2 Diabetes Mellitus, Metabolic Syndrome, Impaired Glucose Tolerance, Disorder of Glucose Regulation
Interventions
Metformin XR plus placebo, Metformin XR plus liraglutide
Drug
Lead sponsor
Woman's
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2019
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 26, 2019 · Synced Oct 14, 2026, 7:41 PM EDT
Completed Phase 1 Interventional

Multiple Dose Study of PF-04991532 in Patients With Type 2 Diabetes

NCT01129258
View directory record Official record
Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders
Interventions
PF-04991532, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
4
States / cities
Chula Vista, California • Fountain Valley, California • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2011 · Synced Oct 14, 2026, 7:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of the Effect of LY2189265 on Two Blood Pressure Drugs

NCT01324388
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
LY2189265, Metoprolol, Lisinopril, Placebo
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
3
States / cities
Honolulu, Hawaii • Evansville, Indiana • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2014 · Synced Oct 14, 2026, 7:41 PM EDT
Enrolling by invitation Not applicable Interventional

Feasibility of a Diabetes Self-Management Program With Continuous Glucose Monitoring for Adults With Type 2 Diabetes

NCT07743307
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
The DECIDE Self-Management Program, Continuous Glucose Monitoring (CGM)
Behavioral
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 14, 2026, 7:41 PM EDT